Host-vs.-altered-host eruptions in patients on liposomal doxorubicin

Journal of Cutaneous Pathology

Volumn 29, Issue 3, 2002, Pages 148-153

  Skelton, Henry ^a   Linstrum, Jill ^b   Smith, Kathleen ^c,d  

^a LABORATORY CORPORATION OF AMERICA   (United States)

^b Washington Clinic   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; DOXORUBICIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CASE REPORT; CLINICAL FEATURE; DRUG DELIVERY SYSTEM; FEMALE; HISTOLOGY; HUMAN; METASTASIS; OVARY CARCINOMA; RASH; SKIN TOXICITY;

ACANTHOSIS NIGRICANS; ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA; CYTOTOXICITY, IMMUNOLOGIC; DOXORUBICIN; DRUG ERUPTIONS; ERYTHEMA; FEMALE; FLUOCINONIDE; GLUCOCORTICOIDS; HUMANS; KERATOSIS; LIPOSOMES; MIDDLE AGED; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

EID: 0036254748     PISSN: 03036987     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0560.2002.290304.x     Document Type: Article

References (20)

1. Anthracycline antibiotics in cancer therapy: Focus on drugs resistance
2. Anthracyclines in the treatment of cancer. An overview
3. Anthracyclines in haematology: Preclinical studies, toxicity and delivery systems
4. A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy
5. Padiation-adriamycin interactions: Preliminary clinical observations
6. Adiamycin and enhanced radiation reaction in normal esophagus and skin
7. Reduction of doxorubicin cardiotoxicity by prolonged continuous IV infusion
8. Risk factors for doxorubin-induced congestive heart failure
9. Anthracycline cardiac toxicity by dexazoxane breakthough of a barrier - Sharpens antitumor profile and therapeutic index
10. Liposomes as carriers of cancer chemotherapy: Cancer status and future prospects
11. Liposomal anthracyclines
12. Polyethylene-glycol coated (pegylated) liposomal doxorubicin rationale for use in solid tumors
13. Clinical efficacy and prospects for use of pegylated liposomal soxorubicin in the treatment of ovarian and breast cancers
14. Safety aspects of pegylated liposomal doxorubicin in patients with cancer
15. Comparison of pharmacokinetics (PK) of free and liposome encapsulated soxurubicin in advanced cancer patients
16. Antiboy-targeted delivery of doxirubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice
17. Liposomal doxorubicin, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of patients with AIDS-related Kaposi's sarcoma
18. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumour activity and toxicity modification by liposomal encapsulation
19. Leukemia following chemotherapy for ovarian cancer
20. P-glycoprotein expression and function in circulating blood cells from normal volunteers